Background and Objectives It is well known that anti-platlet agents decrease the rate of subacute thrombosis after intracoronary stenting significantly. The aim of this study is to assess the antithrombotic effect and safety of 2-month combined regimen of cilostazol and aspirin on intracoronary stenting. Methods The study population consisted of 78 lesions of 57 patients age 58.1 10.3, male 47, female 10 with ischemic heart disease who were underwent successful intracoronary stenting. They were received cilostazol 200 mg/day and aspirin 100 mg/day two days before intracoronary stenting and continued for 8 weeks, and then aspirin was medicated continuously during the study. The laboratory and clinical findings were evaluated before cilostazol administration, 4 weeks, 8 weeks and 6 months after intervention. The treadmill excercise test was done at 6 months after intervention. Results Subacute thrombosis occurred in 2 patients 3.5% . Target lesion revascularization TLR was done in 4 patients 7.3% . Clinical restenosis symptomatic or positive stress test, subacute thrombosis and TLR occurred in 15 patients 26.3% . There was no granulocytopenia, or severe liver dysfunction. HDL-cholesterol was increased significantly at 2 months 36.6 7.4 mg/dl versus 41.6 9.3 mg/dl. p 0.01 and 6 months 36.6 7.4 mg/dl versus 42.4 10.6 mg/dl. p 0.01 follow up. Conclusion Two-month combined regimen of cilostazol and aspirin was effective and safe after intracoronary stenting. Subacute thrombosis and clinical restenosis rate were comparable with pervious reports. Further large randomized trials are needed for the evaluation of favorable effect of cilostazol on lipid metabolism. Korean Circulation J 2000 ; 30 8 : 927-936 KEY WORDS Cilostazol Intracoronary stenting Subacute thrombosis Target lesion revascularization.

